Get the Stockscreener App
2.30
2.95%
-0.07
After Hours:
2.30
Oramed Pharmaceuticals, Inc stock is currently priced at $2.30, with a 24-hour trading volume of 107.26K.
It has seen a -2.95% decreased in the last 24 hours and a -16.67% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.35 pivot point. If it approaches the $2.27 support level, significant changes may occur.
Previous Close:
$2.37
Open:
$2.37
24h Volume:
107.26K
Market Cap:
$90.73M
Revenue:
$2.70M
Net Income/Loss:
$5.53M
P/E Ratio:
-4.5098
EPS:
-0.51
Net Cash Flow:
$-10.55M
1W Performance:
+4.55%
1M Performance:
-16.67%
6M Performance:
+19.79%
1Y Performance:
+5.02%
1D Range:
$2.1999
$2.37
52W Range:
$1.67
$5.25
Oramed Pharmaceuticals, Inc Stock (ORMP) Company Profile
Name
Oramed Pharmaceuticals, Inc
Sector
Industry
Phone
844-967-2633
Address
142 West 57th Street, 11th floor, New York, NY
Oramed Pharmaceuticals, Inc Stock (ORMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-20-21 | Initiated | Canaccord Genuity | Buy |
| Feb-09-21 | Initiated | National Securities | Buy |
| Dec-03-20 | Initiated | Alliance Global Partners | Buy |
| Mar-11-20 | Initiated | Aegis Capital | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-17 | Resumed | B. Riley FBR, Inc. | Buy |
| May-26-16 | Reiterated | FBR Capital | Outperform |
| Dec-01-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-19-15 | Initiated | FBR Capital | Outperform |
| Apr-13-15 | Resumed | MLV & Co | Buy |
| Jan-30-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Initiated | MLV & Co | Buy |
| Dec-03-13 | Initiated | Aegis Capital | Buy |
View All
Oramed Pharmaceuticals, Inc Stock (ORMP) Latest News
Oramed Pharmaceuticals, Inc Stock (ORMP) Financials Data
Oramed Pharmaceuticals, Inc (ORMP) Revenue 2024
ORMP reported a revenue (TTM) of $2.70 million for the quarter ending June 30, 2023, a +0.22% rise year-over-year.
Oramed Pharmaceuticals, Inc (ORMP) Net Income 2024
ORMP net income (TTM) was $5.53 million for the quarter ending December 31, 2023, a +115.11% increase year-over-year.
Oramed Pharmaceuticals, Inc (ORMP) Cash Flow 2024
ORMP recorded a free cash flow (TTM) of -$10.55 million for the quarter ending December 31, 2023, a +62.87% increase year-over-year.
Oramed Pharmaceuticals, Inc (ORMP) Earnings per Share 2024
ORMP earnings per share (TTM) was $0.14 for the quarter ending December 31, 2023, a +114.89% growth year-over-year.
About Oramed Pharmaceuticals, Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
9.90%
3.08%
Cap:
|
Volume (24h):